pubmed.ncbi.nlm.nih.gov

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS - PubMed

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS

Adam S Sperling et al. Leuk Lymphoma. 2020 Mar.

No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.

The mutational spectrum is similar between Agent Orange exposed and control MDS patients. (a) Co-mutation plot for driver mutations identified in Agent Orange exposed and control subjects. Syn: synonymous. (b) Mutational signature analysis for subjects exposed to Agent Orange and controls. Colored chart signifies the specific single nucleotide variant and 4 × 4 grid denotes the sequence context. (c) Mutational burden per Mbp for Agent Orange exposed veterans compared to controls.

Similar articles

References

    1. Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5–19. - PMC - PubMed
    1. Ma X Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125(7):S2–S5. - PMC - PubMed
    1. National Academies of Sciences, Engineering, and Medicine. Veterans and Agent Orange: Update 11 2018. Washington (DC) 2018. - PubMed
    1. Chamie K, DeVere White RW, Lee D, et al. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer. Cancer. 2008;113(9):2464–2470. - PubMed
    1. Kramarova E, Kogevinas M, Anh CT, et al. Exposure to Agent Orange and occurrence of soft-tissue sarcomas or non-Hodgkin lymphomas: an ongoing study in Vietnam. Environ Health Perspect. 1998;106 (Suppl 2):671–678. - PMC - PubMed

Publication types

MeSH terms

Substances